Depletion of latent HIV-1 infection in vivo

A proof-of-concept study

Ginger Lehrman, Ian Hogue, Sarah Palmer, Cheryl Jennings, Celsa A. Spina, Ann Wiegand, Alan L. Landay, Robert W. Coombs, Douglas D. Richman, John W. Mellors, John M. Coffin, Ronald J. Bosch, David M. Margolis

Research output: Contribution to journalArticle

400 Citations (Scopus)

Abstract

Background: Persistent infection in resting CD4+ T cells prevents eradication of HIV-1. Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells. Procedures: We did a proof-of-concept study in four volunteers infected with HIV and on highly-active antiretroviral therapy (HAART). After intensifying the effect of HAART with subcutaneous enfuvirtide 90 μg twice daily for 4-6 weeks to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment regimen for 3 months. We quantified latent infection of resting CD4+ T cells before and after augmented treatment by limiting-dilution culture of resting CD4+ T cells after ex-vivo activation. Findings: The frequency of resting cell infection was stable before addition of enfuvirtide and valproic acid, but declined thereafter. This decline was significant in three of four patients (mean reduction 75%, range 68% to >84%). Patients had slight reactions to enfuvirtide at the injection site, but otherwise tolerated treatment well. Interpretation: Combination therapy with an HDAC inhibitor and intensified HAART safely accelerates clearance of HIV from resting CD4+ T cells in vivo, suggesting a new and practical approach to eliminate HIV infection in this persistent reservoir. This finding, though not definitive, suggests that new approaches will allow the cure of HIV in the future.

Original languageEnglish (US)
Pages (from-to)549-555
Number of pages7
JournalLancet
Volume366
Issue number9485
DOIs
StatePublished - Aug 13 2005
Externally publishedYes

Fingerprint

HIV Infections
HIV-1
HIV
T-Lymphocytes
Highly Active Antiretroviral Therapy
Valproic Acid
Histone Deacetylase Inhibitors
Infection
Histone Deacetylase 1
Chromatin Assembly and Disassembly
Therapeutics
Volunteers
Injections
Enzymes
enfuvirtide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lehrman, G., Hogue, I., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., ... Margolis, D. M. (2005). Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet, 366(9485), 549-555. https://doi.org/10.1016/S0140-6736(05)67098-5

Depletion of latent HIV-1 infection in vivo : A proof-of-concept study. / Lehrman, Ginger; Hogue, Ian; Palmer, Sarah; Jennings, Cheryl; Spina, Celsa A.; Wiegand, Ann; Landay, Alan L.; Coombs, Robert W.; Richman, Douglas D.; Mellors, John W.; Coffin, John M.; Bosch, Ronald J.; Margolis, David M.

In: Lancet, Vol. 366, No. 9485, 13.08.2005, p. 549-555.

Research output: Contribution to journalArticle

Lehrman, G, Hogue, I, Palmer, S, Jennings, C, Spina, CA, Wiegand, A, Landay, AL, Coombs, RW, Richman, DD, Mellors, JW, Coffin, JM, Bosch, RJ & Margolis, DM 2005, 'Depletion of latent HIV-1 infection in vivo: A proof-of-concept study', Lancet, vol. 366, no. 9485, pp. 549-555. https://doi.org/10.1016/S0140-6736(05)67098-5
Lehrman G, Hogue I, Palmer S, Jennings C, Spina CA, Wiegand A et al. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet. 2005 Aug 13;366(9485):549-555. https://doi.org/10.1016/S0140-6736(05)67098-5
Lehrman, Ginger ; Hogue, Ian ; Palmer, Sarah ; Jennings, Cheryl ; Spina, Celsa A. ; Wiegand, Ann ; Landay, Alan L. ; Coombs, Robert W. ; Richman, Douglas D. ; Mellors, John W. ; Coffin, John M. ; Bosch, Ronald J. ; Margolis, David M. / Depletion of latent HIV-1 infection in vivo : A proof-of-concept study. In: Lancet. 2005 ; Vol. 366, No. 9485. pp. 549-555.
@article{fcc35167094241399bb0ab351c9169dc,
title = "Depletion of latent HIV-1 infection in vivo: A proof-of-concept study",
abstract = "Background: Persistent infection in resting CD4+ T cells prevents eradication of HIV-1. Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells. Procedures: We did a proof-of-concept study in four volunteers infected with HIV and on highly-active antiretroviral therapy (HAART). After intensifying the effect of HAART with subcutaneous enfuvirtide 90 μg twice daily for 4-6 weeks to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment regimen for 3 months. We quantified latent infection of resting CD4+ T cells before and after augmented treatment by limiting-dilution culture of resting CD4+ T cells after ex-vivo activation. Findings: The frequency of resting cell infection was stable before addition of enfuvirtide and valproic acid, but declined thereafter. This decline was significant in three of four patients (mean reduction 75{\%}, range 68{\%} to >84{\%}). Patients had slight reactions to enfuvirtide at the injection site, but otherwise tolerated treatment well. Interpretation: Combination therapy with an HDAC inhibitor and intensified HAART safely accelerates clearance of HIV from resting CD4+ T cells in vivo, suggesting a new and practical approach to eliminate HIV infection in this persistent reservoir. This finding, though not definitive, suggests that new approaches will allow the cure of HIV in the future.",
author = "Ginger Lehrman and Ian Hogue and Sarah Palmer and Cheryl Jennings and Spina, {Celsa A.} and Ann Wiegand and Landay, {Alan L.} and Coombs, {Robert W.} and Richman, {Douglas D.} and Mellors, {John W.} and Coffin, {John M.} and Bosch, {Ronald J.} and Margolis, {David M.}",
year = "2005",
month = "8",
day = "13",
doi = "10.1016/S0140-6736(05)67098-5",
language = "English (US)",
volume = "366",
pages = "549--555",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9485",

}

TY - JOUR

T1 - Depletion of latent HIV-1 infection in vivo

T2 - A proof-of-concept study

AU - Lehrman, Ginger

AU - Hogue, Ian

AU - Palmer, Sarah

AU - Jennings, Cheryl

AU - Spina, Celsa A.

AU - Wiegand, Ann

AU - Landay, Alan L.

AU - Coombs, Robert W.

AU - Richman, Douglas D.

AU - Mellors, John W.

AU - Coffin, John M.

AU - Bosch, Ronald J.

AU - Margolis, David M.

PY - 2005/8/13

Y1 - 2005/8/13

N2 - Background: Persistent infection in resting CD4+ T cells prevents eradication of HIV-1. Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells. Procedures: We did a proof-of-concept study in four volunteers infected with HIV and on highly-active antiretroviral therapy (HAART). After intensifying the effect of HAART with subcutaneous enfuvirtide 90 μg twice daily for 4-6 weeks to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment regimen for 3 months. We quantified latent infection of resting CD4+ T cells before and after augmented treatment by limiting-dilution culture of resting CD4+ T cells after ex-vivo activation. Findings: The frequency of resting cell infection was stable before addition of enfuvirtide and valproic acid, but declined thereafter. This decline was significant in three of four patients (mean reduction 75%, range 68% to >84%). Patients had slight reactions to enfuvirtide at the injection site, but otherwise tolerated treatment well. Interpretation: Combination therapy with an HDAC inhibitor and intensified HAART safely accelerates clearance of HIV from resting CD4+ T cells in vivo, suggesting a new and practical approach to eliminate HIV infection in this persistent reservoir. This finding, though not definitive, suggests that new approaches will allow the cure of HIV in the future.

AB - Background: Persistent infection in resting CD4+ T cells prevents eradication of HIV-1. Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells. Procedures: We did a proof-of-concept study in four volunteers infected with HIV and on highly-active antiretroviral therapy (HAART). After intensifying the effect of HAART with subcutaneous enfuvirtide 90 μg twice daily for 4-6 weeks to prevent the spread of HIV, we added oral valproic acid 500-750 mg twice daily to their treatment regimen for 3 months. We quantified latent infection of resting CD4+ T cells before and after augmented treatment by limiting-dilution culture of resting CD4+ T cells after ex-vivo activation. Findings: The frequency of resting cell infection was stable before addition of enfuvirtide and valproic acid, but declined thereafter. This decline was significant in three of four patients (mean reduction 75%, range 68% to >84%). Patients had slight reactions to enfuvirtide at the injection site, but otherwise tolerated treatment well. Interpretation: Combination therapy with an HDAC inhibitor and intensified HAART safely accelerates clearance of HIV from resting CD4+ T cells in vivo, suggesting a new and practical approach to eliminate HIV infection in this persistent reservoir. This finding, though not definitive, suggests that new approaches will allow the cure of HIV in the future.

UR - http://www.scopus.com/inward/record.url?scp=23744500093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744500093&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(05)67098-5

DO - 10.1016/S0140-6736(05)67098-5

M3 - Article

VL - 366

SP - 549

EP - 555

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9485

ER -